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ABSTRACT
Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which 
range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent 
patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic 
advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised 
patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case 
ever been reported in the literature.
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INTRODUCTION
Cancer is the most dreaded disease of the 21st century, and the 
frequency of its occurrence in adults is 2.7 times more than in children 
and lymphomas contribute to almost 18% [1]. Infection with human 
immunodeficiency virus (HIV) predisposes to the development of 
neoplasm including lymphoma [2,3]. Primary effusion lymphoma is 
one of the least common of the AIDS-related lymphomas, accounting 
for 1–4% of all cases [4,5]. Plasmablastic lymphoma (PBL) is a rare 
subtype of diffuse large B-cell lymphoma associated with HIV patients. 
Its presentation as primary central nervous system (CNS) effusion 
lymphomas is even rarer, in which there is no detectable tumor in the 
individual.
CASE REPORT
A 45-year immunocompromised male, presented to the neurosurgery 
department of Kasturba Hospital with complaint of headache, and 
altered sensorium for 15 days with no fever, neck rigidity, weight loss, 
organomegaly, or lymphadenopathy. Both plain computed tomography 
and magnetic resonance imaging of the brain yielded essentially 
normal findings. Papanicolaou-stained smears of cerebrospinal fluid 
(CSF) from the patients were examined. The smears showed increased 
cellularity with flourishing abnormal plasmacytoid cells (Fig. 1). 
Immunohistochemistry was attempted on cell block but was not 
processed due to scanty cell yield. Flow cytometry on fresh CSF sample 
was performed. The neoplastic cells showed plasmacytic differentiation 
with expression of bright CD38 and CD56 in approximately 67–70% 
of the total cells. These cells were also negative for CD79a and CD19. 
Interestingly, the neoplastic cells were not restricted for both kappa 
and lambda light chain, signifying non-secretory phenotype. Protein 
electrophoresis showed a normal pattern.
DISCUSSION
PBL is a rare phenotype presenting as primary CNS effusion 
lymphoma. To the best of our knowledge, till date, there is no 
reference in the literature of this type of presentation of PBL. PBL is 
known as one of the most aggressive forms of lymphoma and now 
has been accepted by the WHO as one of the subtypes of diffuse 
large B-cell lymphoma [6]. Since the first description of PBL, in 1997, 
by Delecluse et al. [7], the spectrum of PBL involvement of various 
organs has widened. Various sites from where it has been reported 
include skin [8], breast [9], gastrointestinal [10], central nervous 
system [11], male genitourinary system, and bone [12]. It is rarely 
found in children [13]. PBL is characterized by B-immunoblast-
like cells with the expression of immunophenotype as explained 
in mature plasma cells [14]. Morphologically, PBL cells have two 
subtypes described in literature [15], first, which is most common 
is characterized by monomorphic neoplastic cells with minimal 
or no plasmacytic differentiation. The second type includes PBL 
with plasmacytic differentiation which shows tumor cells with 
differentiation to mature plasma cells, i.e., round-to-oval cells with an 
eccentric nucleus and some with prominent nucleolus. Sometimes, a 
very conspicuous perinuclear hof in the cytoplasm may be seen [16]. 
Epstein–Barr Virus, a human gamma herpesvirus, infects almost 90% 
of population worldwide and is associated with the development of 
B-cell lymphomas [17]. It is also found in most of the plasmablastic 
cases, whereas human herpesvirus 8 (HHV8) is absent [18]. We were 
unable to go further with immunology for Epstein-Barr virus or HHV8 
as the patient was lost to follow-up.
CONCLUSION
Primary CNS effusion lymphoma of non-secretory plasmablastic 
type is the rarest phenomenon to be reported in the literature. When 
there is an established hematological or solid organ malignancy, the 
abnormal CSF cells can be easily subcategorized, but for a primary CNS 
effusion lymphoma, concurrent flow cytometry, and cytomorphological 
evaluation are the most appropriate to come to an acceptable 
conclusion.
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Fig. 1: Papanicolaou stain (×400) cerebrospinal fluid smear 
showing bizarre plasmacytoid cells
